| Not Yet Recruiting | A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gyn NCT07408648 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | Romiplostim N01 for Chemotherapy-induced Thrombocytopenia NCT07063225 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients NCT07043894 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in NCT06809101 | Pomeranian Medical University Szczecin | — |
| Recruiting | Single Arm Romiplostim to Prevent CIT NCT07048249 | Children's Hospital Medical Center, Cincinnati | EARLY_Phase 1 |
| Unknown | Romiplostim in Chemotherapy-Induced Thrombocytopenia NCT06201663 | Ain Shams University | Phase 3 |
| Active Not Recruiting | Avatrombopag vs. Placebo for CIT in GI Malignancies NCT05772546 | Hanny Al-Samkari, MD | Phase 2 |
| Unknown | The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Pat NCT06099925 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Unknown | Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma NCT05969158 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leu NCT05944211 | RenJi Hospital | Phase 2 |
| Active Not Recruiting | Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. NCT05864014 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia NCT05554913 | Qilu Pharmaceutical Co., Ltd. | Phase 2 / Phase 3 |
| Completed | A Study of PN20 in Healthy Adult Volunteers NCT06523088 | Chongqing Peg-Bio Biopharm Co., Ltd. | Phase 1 |
| Withdrawn | A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tu NCT05261646 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Recruiting | Herombopag for Chemotherapy-induced Thrombocytopenia NCT05236582 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Avatrombopag for Chemotherapy-induced Thrombocytopenia NCT05218226 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Completed | Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia NCT05851027 | Qilu Pharmaceutical Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | Eltrombopag for Chemotherapy-induced Thrombocytopenia NCT04600960 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Completed | To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatmen NCT05688306 | Liaoning Cancer Hospital & Institute | — |
| Active Not Recruiting | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Canc NCT03937154 | Amgen | Phase 3 |
| Completed | Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. NCT03976882 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancre NCT03362177 | Amgen | Phase 3 |
| Completed | Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematologica NCT03471078 | Sobi, Inc. | Phase 3 |
| Withdrawn | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. NCT03343847 | Amgen | Phase 3 |
| Unknown | A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-in NCT03049774 | Angde Biotech Pharmaceutical Co., Ltd. | — |
| Completed | A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 NCT01663441 | Beijing Northland Biotech. Co., Ltd. | Phase 3 |
| Completed | Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Throm NCT01933035 | Beth Israel Medical Center | — |
| Terminated | A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytop NCT01345214 | Ono Pharma USA Inc | Phase 1 |
| Terminated | Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients NCT00926354 | BioMAS Ltd | Phase 2 |
| Completed | Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell NCT00413283 | Amgen | Phase 2 |
| Completed | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With NCT00283439 | Amgen | Phase 1 / Phase 2 |